Publications
145
Citations
736
Est. group size
~8
Recurring co-author estimate
Active years
12
Publishing since 2015
Vineeth Sukrithan's research focuses on neuroendocrine tumors (rare cancers arising from hormone-producing cells) and lung cancer, including clinical trials of new radioactive and targeted treatments, patient quality-of-life studies, and laboratory investigations into how smoking-related inflammation contributes to lung cancer development. Their work spans both clinical trial research (testing new drugs and treatment combinations in patients) and more basic studies of tumor biology and immune responses.
Publication output has grown substantially over the past decade, rising sharply from just a few papers per year before 2022 to over 50 in 2023 and 44 in 2025, indicating a strong recent increase in research activity.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Assessing Patient Characteristics in Neuroendocrine Tumor Research: A Comparison of the NET-PRO Study to SEER Population-Based Data
Endocrine · 2026
- Safety and preliminary efficacy results of [ <sup>212</sup> Pb]VMT-a-NET in advanced somatostatin receptor subtype 2 (SSTR2)-expressing neuroendocrine tumors (NETs).
Journal of Clinical Oncology · 2026
- Abstract CT088: [212Pb]VMT-a-NET in advanced SSTR2+ neuroendocrine tumors: safety and preliminary efficacy results from dose-finding cohorts 1,2 and 3
Cancer Research · 2026
- Using a participation monitoring database to enhance recruitment in a rare cancer population
Journal of Clinical and Translational Science · 2026
- Quality of life and care experiences in a US multi-institutional neuroendocrine tumor cohort
JNCI Journal of the National Cancer Institute · 2026
- Abstract CT185: A phase 1 trial of M3814 (peposertib) in combination with lutetium 177 DOTATATE for metastatic well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Cancer Research · 2026
- Pulmonary neuroendocrine neoplasms: the molecular landscape, therapeutic challenges, and diagnosis and management strategies
The Lancet Oncology · 2025
- Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors
Nature Communications · 2025
- Supplementary Table S1 from Smoking-Associated Carcinogen–Induced Inflammation Promotes Lung Carcinogenesis via IRAK4 Activation
2025
- Data from Smoking-Associated Carcinogen–Induced Inflammation Promotes Lung Carcinogenesis via IRAK4 Activation
2025
- Supplementary Figure S6 from Smoking-Associated Carcinogen–Induced Inflammation Promotes Lung Carcinogenesis via IRAK4 Activation
2025
- Supplementary Table S4 from Smoking-Associated Carcinogen–Induced Inflammation Promotes Lung Carcinogenesis via IRAK4 Activation
2025
- Supplementary Figure S5 from Smoking-Associated Carcinogen–Induced Inflammation Promotes Lung Carcinogenesis via IRAK4 Activation
2025
- Supplementary Figure S1 from Smoking-Associated Carcinogen–Induced Inflammation Promotes Lung Carcinogenesis via IRAK4 Activation
2025
- Supplementary Figure S3 from Smoking-Associated Carcinogen–Induced Inflammation Promotes Lung Carcinogenesis via IRAK4 Activation
2025
- Journal of Clinical Oncology×11
- Cancer Research×7
- Endocrine Abstracts×5
- Regular and Young Investigator Award Abstracts×3
- Thyroid×2
- Ye Zhou
Medicine · The Ohio State University
- Ashima Goyal
Medicine · The Ohio State University
- Bhavana Konda
Medicine · The Ohio State University
- Manisha H. Shah
Medicine · The Ohio State University
- Dramane Konate
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile